Schizophrenia, characterized by delusions, hallucinations, and cognitive impairments, poses significant challenges for individuals and society. This study investigates the effects of adjuvant therapy with folic acid and methylcobalamin on clinical symptoms and brain-derived neurotrophic factor (BDNF) levels in schizophrenia patients receiving risperidone. A total of 46 subjects participated in 8-week experimental analysis, with the treatment group receiving adjuvant therapy alongside risperidone at Department of Psychiatry, Jinnah Post Graduate Medical Centre Karachi. Positive and significant improvements in clinical symptoms (63.33%) and BDNF levels were observed in the treatment group compared to the control group. The study contributes valuable insights into the potential benefits of adjuvant therapy for schizophrenia treatment.
No takes yet. Share an insight, caveat, or question.
Lashari et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: